These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15886075)

  • 41. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine.
    Hare WA; Wheeler L
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2940-8. PubMed ID: 19136701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
    Kato T
    Clin Calcium; 2004 Aug; 14(8):76-80. PubMed ID: 15577101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glutamate preconditioning prevents neuronal death induced by combined oxygen-glucose deprivation in cultured cortical neurons.
    Lin CH; Chen PS; Gean PW
    Eur J Pharmacol; 2008 Jul; 589(1-3):85-93. PubMed ID: 18589412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological characterization, localization, and regulation of ionotropic glutamate receptors in skate horizontal cells.
    Kreitzer MA; Birnbaum AD; Qian H; Malchow RP
    Vis Neurosci; 2009; 26(4):375-87. PubMed ID: 19678977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons.
    Noh J; Lee ES; Chung JM
    J Neurochem; 2009 Jun; 109(5):1261-71. PubMed ID: 19302475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees.
    Schley M; Topfner S; Wiech K; Schaller HE; Konrad CJ; Schmelz M; Birbaumer N
    Eur J Pain; 2007 Apr; 11(3):299-308. PubMed ID: 16716615
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release.
    Chen BT; Moran KA; Avshalumov MV; Rice ME
    J Neurochem; 2006 Feb; 96(3):645-55. PubMed ID: 16405515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits.
    Lapchak PA
    Brain Res; 2006 May; 1088(1):141-7. PubMed ID: 16626666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.
    Gilling KE; Jatzke C; Parsons CG
    Neuropharmacology; 2007 Sep; 53(3):415-20. PubMed ID: 17632186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell proliferation in the hippocampus and in the heart is modified by exposure to repeated stress and treatment with memantine.
    Babic S; Ondrejcakova M; Bakos J; Racekova E; Jezova D
    J Psychiatr Res; 2012 Apr; 46(4):526-32. PubMed ID: 22297273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Memantine in neurological disorders - schizophrenia and depression.
    Czarnecka K; Chuchmacz J; Wójtowicz P; Szymański P
    J Mol Med (Berl); 2021 Mar; 99(3):327-334. PubMed ID: 33447926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder.
    Bisaga A; Danysz W; Foltin RW
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):794-802. PubMed ID: 18573641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels.
    Catterall WA; Striessnig J; Snutch TP; Perez-Reyes E;
    Pharmacol Rev; 2003 Dec; 55(4):579-81. PubMed ID: 14657414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-D-aspartate receptor-gated Ca2+ channels.
    Jaffe DB; Marks SS; Greenberg DA
    Neurosci Lett; 1989 Oct; 105(1-2):227-32. PubMed ID: 2562062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.
    Glodzik L; King KG; Gonen O; Liu S; De Santi S; de Leon MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1005-12. PubMed ID: 18343551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMDA antagonists disrupt timing behaviour in rats.
    Sanger DJ
    Behav Pharmacol; 1992 Dec; 3(6):593-600. PubMed ID: 11224160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is infantile alternating hemiplegia mediated by glutamate toxicity and can it be treated with memantine?
    Korinthenberg R
    Neuropediatrics; 1996 Oct; 27(5):277-8. PubMed ID: 8971751
    [No Abstract]   [Full Text] [Related]  

  • 59. Does the thrifty phenotype result from chronic glutamate intoxication? A hypothesis.
    Hermanussen M; Tresguerres JA
    J Perinat Med; 2003; 31(6):489-95. PubMed ID: 14711105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Memantine: a new hope for treatment of Lewy body-related dementias?
    Emre M
    Lancet Neurol; 2009 Jul; 8(7):594-5. PubMed ID: 19520612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.